This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A new study examined side effect reports of BMCA immunotherapies from the FDA Adverse Event Reporting System, hoping to help inform doctors in their treatment decisions. But these immunotherapies also come with various potentially dangerous side effects. |
After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still trying to work out the logistics of testing and reimbursement. But at least two experts remain positive about the drug’s efficacy and safety profile.
Safety pages on Pharma product websites continue to have high utility. To portray patients, mindless people who blindly believe DTC TV ads and rush to their doctor to ask for a product are inaccurate. If the FDA understood consumer behavior like marketers instead of scientists, they would understand how DTC works.
The FDA needs to study what people do when they see a DTC ad. Today, people don’t see a DTC TV ad and run to their doctor to ask for an Rx. 3hree: DTC marketing minimizes the side effects of prescription drugs – One of the top pages within prescription drug websites continues to be “safety information.”
SUMMARY: The approval of Biogen’s Alzheimer’s drug, after its advisory panel turned it down, begs the Inspector General to open an investigation into the FDA. The FDA gave approval to a medication despite a strong NO vote from their advisory panel of scientific advisers. Where to start? John Carroll, Endpoints.
Accelerated Approval allows for early access to drugs and biologics based on initial evidence of safety and effectiveness, while confirmatory studies required to verify clinical benefits are ongoing. The program was codified into law under the Food and Drug Safety and Innovation Act (FDASIA) in 2012. Do patients care?
The old belief is that patients who are interested in new treatments ask their doctor about them. The FDA can be myopic when researching how consumers view and react to DTC. They’re going to go online where they can read the safety warnings that too often than not scare them because they lack context.
Unlike traditional businesses, pharma brands face strict advertising regulations , requiring compliance with FDA guidelines, HIPAA, and Googles healthcare ad policies. Strict ad copy guidelines , including FDA-mandated fair balance requirements. Include safety disclaimers For branded drug ads, always mention risks and side effects.
It must convert visitors into leads , provide clear and accurate medical information , and ensure compliance with FDA, HIPAA, and ad platform policies. Avoid misleading claims Always align with FDA-approved language. Request a Free Sample for HCPs or Find a Doctor Near You for patients). Heres how to ensure yours is effective.
Consistently we heard that they like images of real patients or a REAL doctor with one key message communicated. 6ix: Safety information needs context. They understand that patient content could be edited to meet FDA requirements, but they like reading others’ experiences managing their health issues.
The US Food and Drug Administration (FDA) have published initial guidance deliberating how ethical it is for children to take part in research trials. Thus, numerous drugs and medical devices approved and licensed by the FDA are missing essential paediatric-specific information on their product labels.
Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD) in the next few months, with a view to making it available in sometime around the middle of 2023.
The US Food and Drug Administration (FDA) has granted approval to Amgen and AstraZeneca ’s Tezspire (tezepelumab-ekko) for self-administration using a single-use, pre-filled pen for severe asthma patients aged 12 years and above. Asthma control improvement and safety profile were consistent with previous clinical trials.
The FDA has published draft guidance giving its position on the ethical reasons for including children in clinical trials, and protecting them from harm. Trial sponsors are still left with the challenge of including children in an ethical , safe, and secure way, and the new guidance is the FDA’s attempt to make that easier to achieve.
Landing pages should also adhere to FDA requirements, clearly displaying ISI (Important Safety Information) and PI (Prescribing Information) where applicable. Download Patient Brochure or Find a Doctor Near You) should align with user intent and stage in the funnel. Clear calls to action (e.g.,
The diabetic macular oedema (DME) space recently witnessed a new approval; the US Food and Drug Administration (FDA) announced the approval of Coherus’ Cimerli (ranibizumab-eqrn; FYB201), a vascular endothelial growth factor (VEGF) inhibitor therapy. Thus, the biosimilar presented a similar efficacy to the reference product.
Healthcare professionals, consumers, medical device businesses, and doctors can better grasp challenging medical ideas, procedures, and gadgets by means of visually immersive and extremely detailed animations. Experience with regulatory standards Medical knowledge is strictly controlled. Increase engagement at trade shows and conferences.
Prediction 1: the FDA will become more directive and collaborative on guidelines for DCTs. The risk of not having these discussions is to conduct expensive trials only to discover too late that they were measuring the wrong endpoint, in the wrong way, or with a tool or technology the FDA does not accept.
The FDA approval is significant as it recognizes the safety and effectiveness of iTFlow® in analyzing blood flow through 4D Flow MRI data, with the potential to enhance diagnostic accuracy for patients with cardiovascular diseases and heart conditions. iTFlow® is an innovative software solution developed by Cardio Flow Design Inc.
Across LabCorp , we innovate through science and technology, with access to approximately 2,500 [doctors] and PhDs and over 700 patients. This reach allows us to support 82% of the novel drugs and therapeutic products approved by the US FDA, including 63% of those specific to oncology,” Reddy states.
The development of software applications that are available with a prescription took a major step forward last year with the first FDA approval for a mobile medical application with both a safety and efficacy label.
From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021.
Next, pharmacists review the participant’s genetic results – along with health data such as drug, lifestyle, and food interactions – to customize a “Medication Action Plan” that members’ physicians can access to determine which drugs should be prescribed to increase safety and efficacy.
Med Device Department: Medicare Sets Precedent for Virtual Reality Therapeutic Payments In November 2021, the FDA approved a virtual reality (VR) therapy that provides an immersive experience for relieving chronic lower back pain. CMS factored in the efficacy of the device as well as its safety beyond the use of opioids. In the U.S.,
Amgen’s (US) Amjevita (adalimumab) is the first Humira biosimilar, launched in February 2023, and seven other FDA-approved biosimilars are expected to arrive on the US market later this year. In addition, two more Humira biosimilars are currently under FDA review and both are anticipated to launch in 2023.
DOCTOR DOCS HCPs Like Pharma Companies—Somewhat Pharma’s public perception has never been entirely favorable, but new data from CMI Media Group shows HCP perception of pharma companies is on the rise. This is an innovative solution to an aggressive cancer using the company’s FDA-approved Bispecific T-cell Engager (BiTE®) molecule.
Food & Drug Administration (FDA) classifies medical devices. They have regulatory controls and marketing pathways you have to follow based on the risk of your device and its overall safety and effectiveness. How the FDA Classifies Medical Devices. They are not obligated to submit data or information to the FDA. .
For pharma marketers, these platforms provide an efficient way to reach doctors, caregivers, and patients while complying with strict regulations. Include mandatory safety information and legal disclaimers. Thats the power of programmatic advertising. Ensure ads target appropriate audiences (e.g., HCPs vs. general consumers).
Another key factor to consider is the safety profile of the drug, particularly with regard to amyloid-related imaging abnormalities (ARIA) that are always a risk with amyloid-targeting drugs, causing oedema (ARIA-E) and haemorrhages (ARIA-H). . “What we cannot know yet is whether that effect increases over time in an individual.
From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021.
Patients and doctors went from trying to make sense of the platform to full-blown adoption where practices continue to incorporate it as an integral part of the go-to-market model. Telehealth has brought positive change for both patients and doctors. Be sure to give your team the psychological safety they need to ask questions.
If a rep takes a more practical view of how to sell their product, they can find accessible staff members play a vital role in the doctor’s decision-making process. . Of course, the FDA and other government agencies have the final say, but in-between organizations like PHRMA are continually changing their rules.
Doctors, caregivers, life sciences companies, and even companies in other industries have attempted to answer this question for as long as medications have been available. Needles cause patients pain, anxiety, pose safety risks, and for some people receiving injection therapy is a traumatic experience. But it is not a simple answer.
Digital therapeutics company Woebot Health has announced enrolment of the first patient in a pivotal clinical trial to evaluate the safety and efficacy of WB001, an investigational therapeutic for postpartum depression (PPD), granted Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2021. Levy asked.
Food & Drug Administration (FDA). It will also help patients set appropriate expectations around safety, efficacy, and their potential eligibility for your investigational drug. While most FDA regulations are largely fixed, guidelines on how to interpret those regulations continue to evolve.
Patient-Centric Marketing: Putting Patients First Pharma marketing is no longer just about doctors and decision-makers. Regulatory Compliance: Marketing teams must stay updated on guidelines from the FDA, EMA, and other regulatory bodies. Compliance isnt a hurdleits an opportunity to showcase your commitment to safety and quality.
We are more confident than ever that this groundbreaking technology will ultimately become the first-line treatment of choice for men and their doctors.” ” The company anticipates using the one-year follow-up data from the VAPOR 2 study in support of an FDA submission for U.S. Francis Medical, Inc., clinical sites.
Patients and doctors went from trying to make sense of the platform to full-blown adoption where practices continue to incorporate it as an integral part of the go-to-market model. Telehealth has brought positive change for both patients and doctors. Be sure to give your team the psychological safety they need to ask questions.
One of the primary objectives of pharma marketing is to communicate the benefits and safety profiles of medications to healthcare providers and patients. This involves a combination of direct-to-consumer advertising, professional marketing to doctors and pharmacists, and educational campaigns.
Collaborate with Influencers in Healthcare Partnering with respected doctors, researchers, and medical professionals allows you to leverage their authority and trust. Highlight Approvals Clearly display any regulatory approvals, such as FDA clearance, to build credibility and trust.
The FDA defines digital health this way. From mobile medical apps and software that support the clinical decisions doctors make every day to artificial intelligence and machine learning, digital technology has been driving a revolution in health care. What is digital health? Hacking medical devices remotely.
Lower DCT usage for Phase I studies may be accounted for due to the heavier focus on safety and efficacy, and increased monitoring of trial participants in-person. In the US, the FDA (Food and Drug Administration) granted accelerated approvals of medical devices with AI in 2022 [8] , and growing use is expected throughout 2023.
While I like traditional blinded market research projects or online virtual panels, the participants tend to be the “engaged patients” and may not account for the doctor-dependent patients needed to reach to move the market. In April, the FDA released an updated draft guidance identifying steps to improve diversity in clinical trials.
Providers, such as doctors and nurses, influence purchasing decisions as they use the products daily. The industry has strict rules to ensure the safety and effectiveness of medical devices. This means following guidelines from organizations like the FDA and being transparent in communication.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content